{"id":773067,"date":"2023-07-27T11:10:52","date_gmt":"2023-07-27T15:10:52","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/horizon-therapeutics-plc-announces-2023-rareis-global-advocate-grant-recipients\/"},"modified":"2023-07-27T11:10:52","modified_gmt":"2023-07-27T15:10:52","slug":"horizon-therapeutics-plc-announces-2023-rareis-global-advocate-grant-recipients","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/horizon-therapeutics-plc-announces-2023-rareis-global-advocate-grant-recipients\/","title":{"rendered":"Horizon Therapeutics plc Announces 2023 #RAREis Global Advocate Grant Recipients"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Horizon Therapeutics plc Announces 2023<i> #RAREis <\/i>Global Advocate Grant Recipients<\/b><\/p>\n<p class=\"bwalignc\"><i>Fifty patient advocacy organizations from around the world awarded a $5,000 grant to address unique challenges faced in rare disease communities<\/i><\/p>\n<p>DUBLIN&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nHorizon Therapeutics plc (Nasdaq: HZNP) today announced the 50 awardees from around the world selected to receive the 2023 <i>#RAREis\u2122 <\/i>Global Advocate Grant. These rare disease patient advocacy organizations will receive a one-time grant of $5,000 to establish new programs, develop educational resources and expand their current offerings to support their disease communities.<\/p>\n<p>\n\u201cAt Horizon, our inclusive approach to supporting patient advocacy groups helps these organizations address the most critical needs affecting their rare disease community,\u201d said Matt Flesch, vice president, communications and patient advocacy, Horizon. \u201cWe learn from every rare disease organization we interact with and are inspired by the diversity of initiatives advancing education, treatments and more. We find great meaning and purpose in this opportunity to help many different organizations \u2013 none of whom operate within any of the disease areas where Horizon makes medicines available \u2013 advance their mission.\u201d<\/p>\n<p>\nThe 2023 <i>#RAREis<\/i> Global Advocate Grant program was <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fir.horizontherapeutics.com%2Fnews-releases%2Fnews-release-details%2Fhorizon-therapeutics-plc-opens-applications-rareis-global&amp;esheet=53486335&amp;newsitemid=20230727028936&amp;lan=en-US&amp;anchor=announced+in+February&amp;index=1&amp;md5=65aa06dc03d000cb5aff5eb002fe55a4\">announced in February<\/a> during Rare Disease Day. Horizon received nearly 190 applications, from 33 countries, representing more than 180 different rare diseases. The 50 organizations awarded the grant in 2023 represent 12 countries and focus on supporting 40 different rare diseases. Eight of the advocacy groups are recipients again this year, enabling continued programming from 2022.<\/p>\n<p>\n2023 Awardees:<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nAlian\u00e7a Distrofia Brasil<\/p>\n<\/li>\n<li>\nAlliance for Pulmonary Hypertension<\/p>\n<\/li>\n<li>\nAssociazione Italiana Sindrome di Beckwith-Wiedemann ODV<\/p>\n<\/li>\n<li>\nAssociazione Sindrome di Noonan e RASopatie ODV<\/p>\n<\/li>\n<li>\nAvery&#8217;s Hope<\/p>\n<\/li>\n<li>\nBeck-Fahrner Syndrome Foundation<\/p>\n<\/li>\n<li>\nBrazilian Association of Prader-Willi Syndrome<\/p>\n<\/li>\n<li>\nBulgarian Society of the Patients with PH<\/p>\n<\/li>\n<li>\nCACNA1A Foundation, Inc.<\/p>\n<\/li>\n<li>\nChordoma Foundation<\/p>\n<\/li>\n<li>\nConRett ETS<\/p>\n<\/li>\n<li>\nDEBRA Ireland<\/p>\n<\/li>\n<li>\nEBF3 HADDS Foundation<\/p>\n<\/li>\n<li>\nEuropean Huntington Association<\/p>\n<\/li>\n<li>\nErdheim-Chester Disease Global Alliance<\/p>\n<\/li>\n<li>\nFoundation for Sarcoidosis Research<\/p>\n<\/li>\n<li>\nGACI Global<\/p>\n<\/li>\n<li>\nGlanzmann&#8217;s Research Foundation, Inc.<\/p>\n<\/li>\n<li>\nHealthcare Education Institute<\/p>\n<\/li>\n<li>\nHypertrophic Olivary Degeneration Association<\/p>\n<\/li>\n<li>\nIndo US Organization for Rare Diseases<\/p>\n<\/li>\n<li>\nInstituto Atlas Biosocial<\/p>\n<\/li>\n<li>\nInternational Gaucher Alliance<\/p>\n<\/li>\n<li>\nInternational Patient Organisation for Primary Immunodeficiencies<\/p>\n<\/li>\n<li>\nJansen de-Vries Syndrome Foundation<\/p>\n<\/li>\n<li>\nKoolen de-Vries Syndrome Foundation<\/p>\n<\/li>\n<li>\nLennox-Gastaut Syndrome Foundation<\/p>\n<\/li>\n<li>\nMEPAN Foundation<\/p>\n<\/li>\n<li>\nNederlandse Leverpatienten Vereniging<\/p>\n<\/li>\n<li>\nNF Patients United &#8211; Global Network of Neurofibromatosis Patient Organizations<\/p>\n<\/li>\n<li>\nNGO Rare Diseases of Ukraine<\/p>\n<\/li>\n<li>\nNorthern Ireland Rare Disease Partnership<\/p>\n<\/li>\n<li>\nOsteogenesis Imperfecta Foundation<\/p>\n<\/li>\n<li>\nPediatric Epilepsy Surgery Alliance<\/p>\n<\/li>\n<li>\nProgressive Familial intrahepatic Cholestasis Network<\/p>\n<\/li>\n<li>\nPhilippine Society for Orphan Disorders, Inc.<\/p>\n<\/li>\n<li>\nParoxysmal Nocturnal Hemoglobinuria Ukraine<\/p>\n<\/li>\n<li>\nProject FAVA<\/p>\n<\/li>\n<li>\nRare Disease Ghana Initiative<\/p>\n<\/li>\n<li>\nRecurrent Respiratory Papillomatosis Foundation<\/p>\n<\/li>\n<li>\nSCN2A Italia Famiglie In Rete APS<\/p>\n<\/li>\n<li>\nSHINE Syndrome Foundation<\/p>\n<\/li>\n<li>\nSoft Bones, Inc.<\/p>\n<\/li>\n<li>\nSpinal Leak CSF Foundation<\/p>\n<\/li>\n<li>\nTANGO2 Research Foundation<\/p>\n<\/li>\n<li>\nTBX4Life<\/p>\n<\/li>\n<li>\nThe E.WE Foundation<\/p>\n<\/li>\n<li>\nThe Rory Belle Foundation<\/p>\n<\/li>\n<li>\nUniti per la P.I.P.O. ETS<\/p>\n<\/li>\n<li>\nUsher Syndrome Ireland<\/p>\n<\/li>\n<\/ul>\n<p>\nApplications are evaluated based on the organization\u2019s work to support the rare disease community and how the grant would further their ability to deliver on their missions and goals. For more information about <i>#RAREis<\/i>, the Global Advocate Grant and to view the full list of the recipient organizations, click <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fbit.ly%2F3KfceSd&amp;esheet=53486335&amp;newsitemid=20230727028936&amp;lan=en-US&amp;anchor=here&amp;index=2&amp;md5=b73610d7194b23f617ff102b780fdd54\">here<\/a>.<\/p>\n<p>\nThe <i>#RAREis<\/i> Global Advocate Grant is part of Horizon\u2019s <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2FRAREisCommunity.com&amp;esheet=53486335&amp;newsitemid=20230727028936&amp;lan=en-US&amp;anchor=%23RAREis+program&amp;index=3&amp;md5=bb5493b272b368b7c5f82aff3df4cc6f\"><i>#RAREis<\/i> program<\/a>, which is committed to improving the experience of living with a rare disease, by providing support to many organizations that offer crucial programs and services for people living with rare diseases. The Global Advocate Grant program <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fir.horizontherapeutics.com%2Fnews-releases%2Fnews-release-details%2Fhorizon-therapeutics-plc-launches-rareis-global-advocate-grant&amp;esheet=53486335&amp;newsitemid=20230727028936&amp;lan=en-US&amp;anchor=launched+in+2022&amp;index=4&amp;md5=e454b5feb40be9889e1975d0a5ad7f4a\">launched in 2022<\/a> to provide critical financial assistance and build equity for the rare disease community by fostering growth for advocacy organizations around the world.<\/p>\n<p><b>About <i>#RAREis<\/i><\/b><\/p>\n<p>\nIn February of 2017, Horizon launched the <i>#RAREis<\/i> program aimed at elevating the voices, faces and experiences of people living with rare diseases, as well as highlight programs and resources for the rare disease community. The program is anchored by an Instagram page and website that showcases photos and stories of people touched by rare disease and captures elements of their patient, caregiver or advocate experience. To learn more, visit the <i>#RAREis<\/i><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2FInstagram.com%2FRAREis___&amp;esheet=53486335&amp;newsitemid=20230727028936&amp;lan=en-US&amp;anchor=Instagram&amp;index=5&amp;md5=e137164395b503521ef0f72710f86ae6\">Instagram<\/a> and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2FFacebook.com%2FRAREisUS&amp;esheet=53486335&amp;newsitemid=20230727028936&amp;lan=en-US&amp;anchor=Facebook&amp;index=6&amp;md5=74a542386997aef7390b6767097e42ac\">Facebook<\/a> page and visit the website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2FRAREisCommunity.com&amp;esheet=53486335&amp;newsitemid=20230727028936&amp;lan=en-US&amp;anchor=www.RAREisCommunity.com&amp;index=7&amp;md5=3d2eaf91d86e4dec518329c4446095cf\">www.RAREisCommunity.com<\/a>.<\/p>\n<p><b>About Horizon<\/b><\/p>\n<p>\nHorizon is a global biotechnology company focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune and severe inflammatory diseases. Our pipeline is purposeful: We apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. For more information on how we go to incredible lengths to impact lives, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2FHorizonTherapeutics.com&amp;esheet=53486335&amp;newsitemid=20230727028936&amp;lan=en-US&amp;anchor=www.horizontherapeutics.com&amp;index=8&amp;md5=64c9bcb134f9682ca4357f8ac6055eed\">www.horizontherapeutics.com<\/a> and follow us on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2FTwitter.com%2FHorizonNews&amp;esheet=53486335&amp;newsitemid=20230727028936&amp;lan=en-US&amp;anchor=Twitter&amp;index=9&amp;md5=f3d723598d3a36020b0e05c42ac4eeb7\">Twitter<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fhorizontherapeutics&amp;esheet=53486335&amp;newsitemid=20230727028936&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=10&amp;md5=23c54eb1c868b5c0236dd3adacf60a97\">LinkedIn<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2FInstagram.com%2FHorizonTherapeutics&amp;esheet=53486335&amp;newsitemid=20230727028936&amp;lan=en-US&amp;anchor=Instagram&amp;index=11&amp;md5=6517a16e07418cb748701161c35ade16\">Instagram<\/a> and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2FFacebook.com%2FHorizonTherapeutics&amp;esheet=53486335&amp;newsitemid=20230727028936&amp;lan=en-US&amp;anchor=Facebook&amp;index=12&amp;md5=8db21263999ea7aa80bf213e4687ecae\">Facebook<\/a>.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230727028936r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20230727028936\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20230727028936\/en\/<\/a><\/span><\/p>\n<p><b>U.S. Media:<br \/>\n<\/b><br \/><b>Michelle Rivas<br \/>\n<\/b><br \/>Senior Manager, Communications<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:media@horizontherapeutics.com\">media@horizontherapeutics.com<\/a><\/p>\n<p><b>Ireland Media:<br \/>\n<\/b><br \/><b>Eimear Rigby<br \/>\n<\/b><br \/>Associate Director, Communications<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:erigby@horizontherapeutics.com\">erigby@horizontherapeutics.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Europe Ireland United States North America New York<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Philanthropy Health Other Philanthropy Other Health General Health Pharmaceutical Biotechnology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230727028936\/en\/1460023\/3\/Horizon_Logo_Full-Color_RGB_Registered_Logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Horizon Therapeutics plc Announces 2023 #RAREis Global Advocate Grant Recipients Fifty patient advocacy organizations from around the world awarded a $5,000 grant to address unique challenges faced in rare disease communities DUBLIN&#8211;(BUSINESS WIRE)&#8211; Horizon Therapeutics plc (Nasdaq: HZNP) today announced the 50 awardees from around the world selected to receive the 2023 #RAREis\u2122 Global Advocate Grant. These rare disease patient advocacy organizations will receive a one-time grant of $5,000 to establish new programs, develop educational resources and expand their current offerings to support their disease communities. \u201cAt Horizon, our inclusive approach to supporting patient advocacy groups helps these organizations address the most critical needs affecting their rare disease community,\u201d said Matt Flesch, vice president, communications and patient advocacy, Horizon. \u201cWe &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/horizon-therapeutics-plc-announces-2023-rareis-global-advocate-grant-recipients\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Horizon Therapeutics plc Announces 2023 #RAREis Global Advocate Grant Recipients&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-773067","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Horizon Therapeutics plc Announces 2023 #RAREis Global Advocate Grant Recipients - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/horizon-therapeutics-plc-announces-2023-rareis-global-advocate-grant-recipients\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Horizon Therapeutics plc Announces 2023 #RAREis Global Advocate Grant Recipients - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Horizon Therapeutics plc Announces 2023 #RAREis Global Advocate Grant Recipients Fifty patient advocacy organizations from around the world awarded a $5,000 grant to address unique challenges faced in rare disease communities DUBLIN&#8211;(BUSINESS WIRE)&#8211; Horizon Therapeutics plc (Nasdaq: HZNP) today announced the 50 awardees from around the world selected to receive the 2023 #RAREis\u2122 Global Advocate Grant. These rare disease patient advocacy organizations will receive a one-time grant of $5,000 to establish new programs, develop educational resources and expand their current offerings to support their disease communities. \u201cAt Horizon, our inclusive approach to supporting patient advocacy groups helps these organizations address the most critical needs affecting their rare disease community,\u201d said Matt Flesch, vice president, communications and patient advocacy, Horizon. \u201cWe &hellip; Continue reading &quot;Horizon Therapeutics plc Announces 2023 #RAREis Global Advocate Grant Recipients&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/horizon-therapeutics-plc-announces-2023-rareis-global-advocate-grant-recipients\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-27T15:10:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230727028936r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/horizon-therapeutics-plc-announces-2023-rareis-global-advocate-grant-recipients\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/horizon-therapeutics-plc-announces-2023-rareis-global-advocate-grant-recipients\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Horizon Therapeutics plc Announces 2023 #RAREis Global Advocate Grant Recipients\",\"datePublished\":\"2023-07-27T15:10:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/horizon-therapeutics-plc-announces-2023-rareis-global-advocate-grant-recipients\\\/\"},\"wordCount\":788,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/horizon-therapeutics-plc-announces-2023-rareis-global-advocate-grant-recipients\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230727028936r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/horizon-therapeutics-plc-announces-2023-rareis-global-advocate-grant-recipients\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/horizon-therapeutics-plc-announces-2023-rareis-global-advocate-grant-recipients\\\/\",\"name\":\"Horizon Therapeutics plc Announces 2023 #RAREis Global Advocate Grant Recipients - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/horizon-therapeutics-plc-announces-2023-rareis-global-advocate-grant-recipients\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/horizon-therapeutics-plc-announces-2023-rareis-global-advocate-grant-recipients\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230727028936r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2023-07-27T15:10:52+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/horizon-therapeutics-plc-announces-2023-rareis-global-advocate-grant-recipients\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/horizon-therapeutics-plc-announces-2023-rareis-global-advocate-grant-recipients\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/horizon-therapeutics-plc-announces-2023-rareis-global-advocate-grant-recipients\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230727028936r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230727028936r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/horizon-therapeutics-plc-announces-2023-rareis-global-advocate-grant-recipients\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Horizon Therapeutics plc Announces 2023 #RAREis Global Advocate Grant Recipients\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Horizon Therapeutics plc Announces 2023 #RAREis Global Advocate Grant Recipients - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/horizon-therapeutics-plc-announces-2023-rareis-global-advocate-grant-recipients\/","og_locale":"en_US","og_type":"article","og_title":"Horizon Therapeutics plc Announces 2023 #RAREis Global Advocate Grant Recipients - Market Newsdesk","og_description":"Horizon Therapeutics plc Announces 2023 #RAREis Global Advocate Grant Recipients Fifty patient advocacy organizations from around the world awarded a $5,000 grant to address unique challenges faced in rare disease communities DUBLIN&#8211;(BUSINESS WIRE)&#8211; Horizon Therapeutics plc (Nasdaq: HZNP) today announced the 50 awardees from around the world selected to receive the 2023 #RAREis\u2122 Global Advocate Grant. These rare disease patient advocacy organizations will receive a one-time grant of $5,000 to establish new programs, develop educational resources and expand their current offerings to support their disease communities. \u201cAt Horizon, our inclusive approach to supporting patient advocacy groups helps these organizations address the most critical needs affecting their rare disease community,\u201d said Matt Flesch, vice president, communications and patient advocacy, Horizon. \u201cWe &hellip; Continue reading \"Horizon Therapeutics plc Announces 2023 #RAREis Global Advocate Grant Recipients\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/horizon-therapeutics-plc-announces-2023-rareis-global-advocate-grant-recipients\/","og_site_name":"Market Newsdesk","article_published_time":"2023-07-27T15:10:52+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230727028936r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/horizon-therapeutics-plc-announces-2023-rareis-global-advocate-grant-recipients\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/horizon-therapeutics-plc-announces-2023-rareis-global-advocate-grant-recipients\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Horizon Therapeutics plc Announces 2023 #RAREis Global Advocate Grant Recipients","datePublished":"2023-07-27T15:10:52+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/horizon-therapeutics-plc-announces-2023-rareis-global-advocate-grant-recipients\/"},"wordCount":788,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/horizon-therapeutics-plc-announces-2023-rareis-global-advocate-grant-recipients\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230727028936r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/horizon-therapeutics-plc-announces-2023-rareis-global-advocate-grant-recipients\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/horizon-therapeutics-plc-announces-2023-rareis-global-advocate-grant-recipients\/","name":"Horizon Therapeutics plc Announces 2023 #RAREis Global Advocate Grant Recipients - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/horizon-therapeutics-plc-announces-2023-rareis-global-advocate-grant-recipients\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/horizon-therapeutics-plc-announces-2023-rareis-global-advocate-grant-recipients\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230727028936r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2023-07-27T15:10:52+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/horizon-therapeutics-plc-announces-2023-rareis-global-advocate-grant-recipients\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/horizon-therapeutics-plc-announces-2023-rareis-global-advocate-grant-recipients\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/horizon-therapeutics-plc-announces-2023-rareis-global-advocate-grant-recipients\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230727028936r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230727028936r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/horizon-therapeutics-plc-announces-2023-rareis-global-advocate-grant-recipients\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Horizon Therapeutics plc Announces 2023 #RAREis Global Advocate Grant Recipients"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/773067","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=773067"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/773067\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=773067"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=773067"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=773067"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}